As you will be aware, the Department for Health and Social Care has asked NICE to conduct an appraisal of ritlecitinib for treating moderate to severe alopecia areata in people 12 years and over.
Please note that the timelines for this appraisal have been revised and the appraisal is now anticipated to begin during mid-October 2022. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission.